Blood will be collected and placed in a 4ml tube without anticoagulants. The tube will be centrifuged and the blood's serum will be isolated in order to examine the biochemical parameters of the study with the cooperation of the Biochemistry Lab of University Hospital AHEPA. Furthermore, 2ml of whole blood will be collected in a tube containing Ethylenediaminetetraacetic acid (EDTA) as the anticoagulant for use in molecular techniques. The whole blood and the serum will be stored in a temperature of -80 degree Celsius.

Acute Lymphoblastic Leukemia

Children that meet all the inclusion criteria for this study will be examined and undergo treatment with asparaginase (Experimental group) and will be compared to the corresponding teams of healthy children and children that have ailed and are off chemotherapy for at least 6 months (Control group).

Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Leukaemia During Therapy With L - Asparaginase

Paediatric and Adolescent Haematology-Oncology Unit, 2nd Department of Paediatrics, Aristotle University of Thessaloniki (AUTH), University General Hospital AHEPA

Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Eukaemia During Therapy With L - Asparaginase.

The genotypes of children with ALL will be recorded and it might constitute an early indicative factor concerning the treatment's outcome. Thusly, essential information will be extracted about the possible contribution of genotype of children under treatment with L-ASP to the lipid disorder as shown in the lab results, to better monitoring of each unique phase of the therapy for clinical occurrences and complication and to faster therapeutic intervention.

During the disease's diagnosis, the lipid profile of the patients' will be determined by measuring the changes of the following parameters compared to the baseline measures: cholesterol (mg/dl), triglycerides(mg/dl), HDL-cholesterol(mg/dl), LDL-cholesterol(mg/dl), apolipoprotein A1(mg/dl), apolipoprotein B100(g/L), lipoprotein α [Lp(α)](nmol/l), glucose (mg/dl), SGOT (U/I), SGPT (U/I), TSH (mU/l) FT4 (pmol/l) amylase (U/I) and lipase (U/I).

Maria Ioannidou

Principal Investigator

Aristotle University Of Thessaloniki

Eskimo-3 Pure Fish Oil, 10 ml per day (2.6 g EPA+DHA)

Leukemia, Acute Lymphoblastic

Eskimo-3 Pure Fish Oil

Rapeseed Oil

Aalborg University Hospital

Aarhus University Hospital

Rigshospitalet

Odense University Hospital

Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia

Effect of Fish Oil Versus Placebo on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia - A Randomized Controlled Trial

Triglycerides and/or total cholesterol levels five times or more than the age-dependent upper normal limit.

Triglycerides, total cholesterol, VLDL-cholesterol, LDL-cholesterol and HDL-cholesterol.

Assessed by self-registration forms, return of bottles and levels of EPA+DHA in whole blood

Assessed by DEXA-scan and bone biomarkers (iCa, PTH, vit D, phosphate, magnesium, creatinine, alkaline phosphatase, CTX, P1NP.

Thromboelastography (TEG), multiplate and thrombocytes.

Cumulative incidence of osteonecrosis, asparaginase associated pancreatitis and thrombosis.

Renate Dagsdottir Laumann

Rigshospitalet, Denmark

Danish Child Cancer Foundation

Participants will be instructed to use the exergaming program at home for 30 mins, 3-5 times per week.

Participants will exercise through exergaming play.

Exergaming Program

University of Minnesota Amplatz Children's Hospital

Exergaming Intervention in ALL Patients

The Effect of a Home-based Fitness Intervention on Cardiometabolic Risk Profile in Acute Lymphoblastic Leukemia (ALL) Patients

The feasibility of an exercise intervention in pediatric ALL patients undergoing maintenance therapy and its effects on markers of cardiometabolic risk. The primary outcome for this pilot study is average minutes and time spent at varying intensity of physical activity per day, as measured by accelerometers.

Estimate of the likely effect size (i.e., difference between the groups in average outcome) of blood pressure.

Estimate of the likely effect size (i.e., difference between the groups in average outcome) of body composition.

Estimate of the likely effect size (i.e., difference between the groups in average outcome) of visceral fat.

Estimate of the likely effect size (i.e., difference between the groups in average outcome) of triglycerides.

University of Minnesota

children aged 6 months - 18 years, diagnosed with an initial episode of INS occurring from the first of July 2011 to the 31st of june 2013.

Nephrotic Syndrome

Azienda Ospedaliera-Universitaria Sant'Orsola Malpighi

PO Salesi, SOS Centro di Riferimento Regionale di Nefrologia e Dialisi Pediatrica

Ospedale Pediatrico Giovanni XXIII

Azienda Ospedaliera Universitaria Meyer, SOD Complessa Nefrologia Pediatrica

Istituto Giannina Gaslini, Dept of Pediatric Nephrology

AOU Policlinico G Martino UOS dipartimentale Nefrologia e Reumatologia pediatrica

Fondazione IRCCS Ca' Granda Ospedale MAggiore Policlinico, UOC Nefrologia e Dialisi

Ospedale dei bambini Di Cristina, UOC Nefrologia Pediatrica

Ospedale degli Angeli, Dept of Pediatrics

Ospedale Pediatrico Burlo Garofalo

Università di Trieste, Department of Life Sciences

Steroid Treatment of Idiopathic Nephrotic Syndrome

Steroid Treatment of Childhood Idiopathic Nephrotic Syndrome: Epidemiology, Therapeutic Adequacy, Medium and Long Term Outcomes. A Prospective Observational Cohort Study.

Giovanni Montini

Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi

IL Sogno di Stefano

Nando and Elsa Peretti Foundation

Psoriasis

lower dose of Acitretin to 17.5 mg/day from 25 mg/day in those experiencing retinoid-related side effects

Acitretin 17.5 mg/day

Mount Sinai Clinical Trials

Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?

An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability

Improvement and maintenance of Psoriasis Area Severity Index (PASI), Body Surface Area (BSA), Physician's Global Assessment (PGA), and Psoriasis Disability Index and Dermatology Life Quality Index (DLQI)

Subjective efficacy/tolerability questionnaires for every subject at the end of the study

leukemia/triglyceride

Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Eukaemia During Therapy With L - Asparaginase.

Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia

Exergaming Intervention in ALL Patients

Steroid Treatment of Idiopathic Nephrotic Syndrome

Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?

Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant

Täydellisin lääketieteellinen tietokanta tieteen tukemana